← All trials
NCT04854044
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2021
- Primary completion
- Jul 1, 2025
- Completion date
- Jul 1, 2026
- First posted
- Apr 22, 2021
- Last posted
- May 12, 2021
- Enrollment
- —
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of California, Los AngelesLead sponsor
- National Cancer Institute (NCI)Collaborator
- Oncoceutics, Inc.Collaborator
- University of California, Los AngelesOverall official - principal investigator
- University of California, Los AngelesCollaborator
- University of California, Los AngelesOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.